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Abstract  24 
Throughout the last decade, significant developments in cellular, molecular, and mouse 25 
models have revealed major endocrine functions of the skeleton.  More recent studies have 26 
evolved the interplay between bone-specific hormones, the skeleton, marrow adipose tissue, 27 
muscle and the brain. This review focuses on literature from the last decade, addressing 28 
endocrine regulation of global energy metabolism via the skeleton. In addition, we will 29 
highlight several recent studies that further our knowledge of new endocrine functions of 30 
some organs; explore remaining unanswered questions; and, finally, we will discuss future 31 
directions for this more complex era of bone biology research.  32 
 33 
Introduction  34 
Bone has long been regarded as an organised collection of inert calcified structures that 35 
facilitate the motility of land animals. The skeleton’s mass and composition provides vital 36 
organ protection, a niche for haematopoiesis, and allows for weight-bearing motion (Guntur 37 
and Rosen 2012; Oldknow, et al. 2015). To facilitate these classical functional roles, and to 38 
maintain bone integrity, there is a continuous homeostatic adjustment of the skeletal 39 
architecture and composition. Central to this adjustment is the highly regulated interplay of 40 
two distinct bone cell types, the osteoblast, and the osteoclast, which have opposing 41 
functions (Crockett, et al. 2011). 42 
 43 
Osteoblasts comprise 5% of all bone cells and facilitate the formation of bone (Florencio-44 
Silva, et al. 2015). Mature osteoblasts synthesise and release type 1 collagen, which forms the 45 
majority (85-90%) of the organic matrix of the bone (Karsenty, et al. 2009). Osteoblasts that 46 
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become embedded in the bone matrix undergo terminal differentiation, giving rise to 47 
osteocytes – the most abundant skeletal cell type (90% of total bone cells) (Dallas and 48 
Bonewald 2010). These immobilised cells are ideally suited to perform the function of 49 
translating mechanical strain into biochemical signals in order to regulate bone composition 50 
(Sugiyama, et al. 2010)(Figure 1). The bone itself is a dynamic organ that is constantly being 51 
remodelled. This is possible due to the unique function of osteoclasts, which mediate 52 
destruction (resorption) of the bone tissue in which they reside (Holtrop and King 1977). The 53 
biphasic action of osteoblasts and osteoclasts enables bone modelling and remodelling. Bone 54 
modelling occurs throughout the lifespan, allowing the bone to adapt altered stresses and 55 
strains put on it (e.g. the tennis players serving arm), whereas, bone remodelling 56 
(maintenance) occurs when the resorbed bone is completely replaced by new bone 57 
(Hadjidakis and Androulakis 2006). The regenerative process of a structure that contributes 58 
to such a large proportion of the body mass (approximately 15% men and 10% in women) 59 
requires an abundance of proteins to be synthesised and secreted. It is therefore plausible 60 
that a high energetic cost is associated with these diverse skeletal functions (Karsenty and 61 
Ferron 2012; Vaananen, et al. 2000).   62 
 63 
From an evolutionary perspective, bones likely represent a strongly selected survival factor 64 
that permitted enhanced movement to allow scavenging, survive injury and therefore the 65 
survival of the organism. However, it is now clear that part of the selection process for bones 66 
involves its integral role in the endocrine control of whole-body energy metabolism (Guntur 67 
and Rosen 2013). One example of the poorly understood metabolic functions of the skeleton 68 
is the presence of adipose tissue within the bone marrow – referred to as marrow adipose 69 
tissue (MAT). Accounting for approximately 10% of the total fat mass in healthy humans, 70 
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the function of MAT and its association with bone-specific cells, namely osteoblasts, 71 
osteocytes and osteoclasts, remains unknown. Here we focus on recent discoveries that 72 
explain the endocrine functions and molecular mechanisms linking bone (inclusive of MAT 73 
and muscle) and energy expenditure.   74 
 75 
 76 
Bone as an endocrine organ  77 
In addition to its structural role, bone is a well-recognised target for endocrine function. This is 78 
exemplified by the orchestrated inter-organ regulation of phosphate, which involves the 79 
parathyroid glands, kidneys, and intestines facilitating homeostatic maintenance of phosphate,  80 
in the mineralisation of bone extracellular matrix (Karsenty and Olson 2016). Implicit to the 81 
theory of homeostatic control is reciprocal crosstalk between the bone and these organs 82 
(Ramsay and Woods 2014). Indeed, the skeleton acts not only as an endocrine target but also as 83 
an endocrine organ with possible roles in the hormonal modulation of systemic energy 84 
homeostasis.  85 
 86 
I) Osteocalcin 87 
Also known as BGP (bone Gla-protein), osteocalcin (OCN) is the most abundant osteoblast-88 
specific non-collagenous protein. OCN is initially synthesised by the osteoblast as a pre–pro-89 
molecule and is commonly used as a serum marker of bone formation  (Brown, et al. 1984). 90 
OCN exists in the general circulation in fully carboxylated, partially carboxylated and 91 
completely uncarboxylated forms (Cairns and Price 1994; Plantalech, et al. 1991; Schilling, et 92 
al. 2005; Vergnaud, et al. 1997). Uncarboxylated OCN is formed when carboxylated OCN in 93 
Page 4 of 37
5 
 
the bone extracellular matrix is decarboxylated by the acidic pH (4.5) in osteoclastic 94 
resorption lacunae. Uncarboxylated OCN promotes β-cell proliferation, insulin secretion, 95 
peripheral insulin sensitivity, energy expenditure and impacts memory and male fertility 96 
(Lee, et al. 2007; Oury, et al. 2013; Oury, et al. 2011). Recently a role for OCN in muscle 97 
function has been demonstrated. OCN levels doubled during endurance exercise in young 98 
adult wild-type (WT) mice, decreased significantly prior to or at mid-life, and OCN failed to 99 
increase during exercise in older mice. Importantly equivalent decreases in circulating OCN 100 
levels were observed in female rhesus monkeys and humans (Mera, et al. 2016a). OCN 101 
administration was sufficient to reverse the age-induced decrease in exercise capacity in 102 
mice. Specifically, in 15-month-old mice, injections of OCN raised circulating OCN levels 103 
more than 4-fold and allowed these mice to run for the same time and distance as 3-month-104 
old mice. Moreover, under-carboxylated OCN promoted uptake and subsequent catabolism 105 
of glucose and fatty acids in myofibres (Mera et al. 2016a; Mera, et al. 2016b). These 106 
nutrients, in turn, facilitate physical adaptation to exercise, whilst concurrently promoting 107 
the exercise-induced release of interleukin-6 (IL-6) from skeletal muscle. IL-6 further drives 108 
the production of bioactive OCN, supporting the hypothesis of a bone-muscle feed-forward 109 
axis. Thus, in addition to its postulated role in glucose and weight homeostasis (Oldknow et 110 
al. 2015), OCN further contributes to the regulation of energy metabolism, through effects on 111 
skeletal muscle. This supports the hypothesis that insulin signalling mediates the link 112 
between bone remodelling, and whole body energy expenditure, and points towards a key 113 
role for the osteoblast in this relationship (Huesa, et al. 2014).  114 
 115 
II) NPP1 and PHOSPHO1 116 
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In order to further increase our knowledge of the skeletons’ endocrine links with energy 117 
expenditure, the role of bone mineralisation factors such as 118 
phosphoethanolamine/phosphocholine phosphatase 1 (PHOSPHO1); ectonucleotide 119 
pyrophosphatase/phosphodiesterase 1 (NPP1) have been addressed. NPP1, encoded by the 120 
Enpp1 gene in mice, is highly abundant in the plasma membrane (external side) and mineral-121 
depositing matrix vesicles of the osteoblast (Mackenzie, et al. 2012). NPP1 generates 122 
inorganic pyrophosphate (PPi) through the hydrolysis of nucleotides (ATP). PPi potently 123 
inhibits hydroxyapatite crystal formation in tissues capable of mineralisation (bone, soft 124 
tissue), and acts as a precursor for inorganic phosphate (Pi) (Buckley, et al. 1990; Mackenzie 125 
et al. 2012). NPP1 regulates glucose homeostasis via suppression of insulin receptor 126 
signalling in various tissues, including adipose, bone, and muscle (Mackenzie et al. 2012; 127 
Maddux, et al. 1995). NPP1 binds to and inhibits insulin-induced receptor conformational 128 
changes and is a potential pathogenic contributor to insulin resistance (Huesa et al. 2014). 129 
This concept is supported by the phenotype of Enpp1 ablated mice, which display improved 130 
glucose homeostasis and resist obesity-associated dysfunction in response to high-fat diet 131 
feeding (Huesa et al. 2014). Thus, NPP1 plays multifaceted roles in normal physiology, 132 
including the regulation of calcium and phosphate homeostasis, inhibition of soft tissue 133 
mineralisation, maintenance of skeletal function and structure regulation of insulin 134 
signalling and energy homeostasis.  135 
 136 
The bone-specific phosphatase PHOSPHO1 is a member of the large haloacid dehalogenase 137 
(HAD) superfamily of Mg2+ dependent hydrolases (Roberts, et al. 2004). PHOSPHO1 is active 138 
inside the osteoblast-derived matrix vesicle, where it scavenges Pi from matrix vesicle 139 
membrane phospholipids to promote intravascular hydroxyapatite deposition. Recent studies 140 
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have identified novel roles of this bone-derived factor in energy homeostasis. Mice with 141 
Phospho1 ablation exhibit a decreased body size and protection against both obesity and 142 
diabetes, regardless of carboxylation status of OCN (Chambers, et al. 2015; Dayeh, et al. 2016; 143 
Oldknow, et al. 2013; Sayols-Baixeras, et al. 2016); however, the mechanisms conferring this 144 
metabolic-protective phenotype remain to be determined.  145 
 146 
III)  PPARγ 147 
The transcription factor PPARγ is critical for differentiation of adipocytes and maintenance of 148 
the adipogenic phenotype. This is achieved via directing lineage commitment of marrow 149 
mesenchymal stem cells from an osteoblast-fate and towards that of adipocytes (Lecka-Czernik 150 
2010). PPARγ insufficiency in mice results in decreased adipose tissue and increased bone mass 151 
via inhibition of osteoclastogenesis and bone resorption (Akune, et al. 2004). It remains unclear 152 
whether increased bone mass is a result of altered lineage commitment of bone marrow stem 153 
cells or an indirect effect through the modified function of adipose tissue. Alternatively, both 154 
direct and indirect mechanisms could account for the bone mass phenotype: PPARγ disruption 155 
in adipose tissue (i.e. lipodystrophic disease) resulted in increased osteoblast activity and 156 
concomitant increased bone formation. The mechanisms by which PPARγ regulates bone is not 157 
clear since mouse models of bone-specific PPARγ conditional knockouts have not been 158 
investigated to date (Cao, et al. 2015). To add further complexity, PPARγ deletion in other 159 
tissues causes profound effects on bone, further complicating investigative efforts. Osteoblast 160 
selective PPARγ deletion in mice (using PPAR(fl/fl):Col3.6-Cre) completely abolished 161 
adipogenesis, with the bone phenotype of increased osteoblastogenesis reflected in primary 162 
bone marrow culture and in isolated bone-marrow stem cells. The pivotal role of PPARγ is 163 
situated at the bifurcation of lineage commitment of bone and adipocytes, suggesting that 164 
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therapeutic manipulation may help to manage obesity-related conditions and orthopaedic 165 
health (Lecka-Czernik 2010). For example, rosiglitazone (an insulin-sensitising 166 
thiazolidinedione) activates PPARγ and effectively treats T2DM by promoting insulin 167 
sensitivity. However, rosiglitazone use comes at a cost of increased fracture risk consistent with 168 
increased adipogenesis and reduced osteoblastogenesis. With a promise for the effective 169 
management of T2DM, further work must continue to determine and thus avoid, any negative 170 
bone-phenotype associated with thiazolidinedione use (Fukunaga, et al. 2015).  171 
 172 
IV) Unexplored Candidates 173 
In light of the newly identified function of bone in energy metabolism, it is of interest to 174 
review the evidence for substrate utilisation in bone cells types. Overexpression of the 175 
glucose transporter Glut1 in osteoblasts enhances osteoblast differentiation and bone 176 
formation (Wei, et al. 2015). Assessment of glucose utilisation by the skeleton in vivo, using 177 
uptake of positon-emitting 18F-fluorodeoxyglucose ([18F]-FDG), revealed greater glucose 178 
uptake in bone than in classical glucose storage and utilisation organs such as the liver, 179 
muscle and white adipose tissue (WAT) (Zoch, et al. 2016). Furthermore, skeletal [18F]-FDG 180 
uptake was greater in young than in older mice, which may be due to the rapid bone 181 
formation in young mice. Intriguingly, insulin administration significantly increased 182 
skeletal accumulation of [18F]-FDG, whilst insulin receptor-deficient and obese mice had 183 
reduced uptake (Zoch et al. 2016). These findings suggest that the skeleton is a 184 
preferential and significant site of glucose uptake that is regulated by insulin and global 185 
metabolism. 186 
 187 
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Bone and adipose tissue 188 
In times of a positive energy balance (i.e. energy intake > energy expenditure) WAT stores 189 
excess energy as triacylglycerol (TAG) and releases fatty acids (FA) and glycerol to be used 190 
for β-oxidation or gluconeogenesis during negative energy balance, respectively (Cahill 191 
2006; Rosen and Spiegelman 2014).  In addition to the role of adipose tissue in energy 192 
storage and release, adipose tissue also provides vital structural/mechanical protection for 193 
organs (e.g. the eye fat, pad, toes, and heel) (Rosen and Spiegelman 2014) and offers a critical 194 
thermoprotective layer against low ambient temperatures. 195 
 196 
Discovery of adipose-derived circulating factors such as adipsin, TNF-α, leptin and 197 
adiponectin (Badman and Flier 2007; Rosen and Spiegelman 2014) defined adipose tissue as 198 
a bona fide endocrine organ. Through the release of these ‘adipokines’, WAT can exert 199 
diverse systemic effects, not only on energy homeostasis but also on other aspects of 200 
physiology such as blood pressure, immune function, and fertility (Michalakis, et al. 2013). 201 
Thus, despite its association with metabolic diseases, WAT performs many essential 202 
physiological functions. Indeed, in the absence, and/or the redistribution of adipose tissue 203 
(lipodystrophy), patients develop insulin resistance, hyperglycemia, hypertriglyceridemia, 204 
hepatic steatosis, and polycystic ovary syndrome underscoring the importance of adipose 205 
formation for normal physiological function (Cortes and Fernandez-Galilea 2015).    206 
 207 
In contrast to white adipocytes, brown adipose tissue (BAT) is specialised for heat 208 
generation by non-shivering thermogenesis. Brown adipocytes, unlike white adipocytes, 209 
have an enrichment of mitochondria that express uncoupling protein-1 (UCP-1). This 210 
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protein uncouples the respiratory chain, allowing protons to pass from the inner-membrane 211 
space to the mitochondrial matrix without passing through ATP synthase. This causes a 212 
futile cycle: oxygen is consumed to pump protons, but the resulting chemi-osmotic gradient 213 
generates no ATP and instead results in the dissipation of energy as heat (Nubel and 214 
Ricquier 2006). BAT is developmentally distinct to WAT, deriving from a distinct lineage 215 
that is shared with skeletal muscle (Rosen and Spiegelman 2014). BAT activity is relatively 216 
high in small mammals and in newborn humans, whereas BAT in adult humans is less 217 
active and is situated deep within the neck and superclavicularly region. Nevertheless, BAT 218 
in adult humans remains cold-responsive, as exemplified in Scandinavian workers exposed 219 
to chronic cold (Huttunen, et al. 1981). Similarly, prolonged cold exposure in rodents has 220 
shown to alter WAT cells by developing a brown fat-like morphology. These cells have been 221 
named “beige” adipocytes, with a gene expression pattern overlapping but distinct to that of 222 
classical BAT (Rosen and Spiegelman 2014; Wu, et al. 2012).  223 
 224 
Whilst these adipose sub-types have received extensive research focus, the MAT within the 225 
marrow cavity of the skeleton has been largely ignored. Concurrent with the emergence of 226 
the field of skeletal energy homeostasis, the research into the form and function of MAT has 227 
begun to expand. Postnatally, MAT forms at distal skeletal sites, including the tailbone, 228 
hands, and feet in mice and humans (Scheller and Rosen 2014). Throughout life, MAT 229 
(yellow marrow) continues to form in areas of the haematopoietic marrow (red marrow) 230 
until almost the entirety of the appendicular skeleton is converted into yellow marrow by 231 
the age of 20 in humans (Moerman, et al. 2004); however, red marrow persists in the axial 232 
skeleton, only declining with advanced age (Justesen, et al. 2001). Marrow adipocytes are 233 
derived from a distinctive progenitor cell that expresses osterix, Prrx1, LepR, and Gremlin1 234 
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(Chen, et al. 2014). Thus, marrow adipocytes may be highly related to osteoblast precursors 235 
and play a role in bone maintenance and skeletal energy (Liu et al., 2013; Mizoguchi et al. 236 
2014).  237 
 238 
MAT consists of two subtypes: constitutive MAT (cMAT) and regulated MAT (rMAT). 239 
cMAT is found predominantly in the distal skeleton, giving the bone marrow a yellow 240 
appearance (Scheller, et al. 2015). In contrast, rMAT develops much later than cMAT, in the 241 
proximal skeleton, hip, ribs and lumbar/thoracic vertebrae postnatally and consists of 242 
adipocytes interspersed with red marrow. rMAT is not necessarily formed in a normal 243 
developmental/physiological manner, instead, rMAT seems to reflect adverse stimuli or 244 
disease states (Pichardo, et al. 2007; Rosen and Spiegelman 2014).  245 
 246 
Many questions remain regarding the formation and function of MAT. In animal models, 247 
MAT increases in response to the contrasting interventions of calorie restriction (CR) and 248 
high-fat diet feeding (Cawthorn, et al. 2014; Devlin, et al. 2010; Doucette, et al. 2015). 249 
Similarly, humans with anorexia nervosa  show MAT expansion (Misra and Klibanski 2013). 250 
Thus, does MAT, like WAT, play a role in regulating systemic energy homeostasis. 251 
Consistent with this possibility, is the suggestion that MAT may function as an energy 252 
reservoir for ectopic lipid, protecting skeletal osteoblasts from lipotoxicity (Gunaratnam, et 253 
al. 2014), as well as secreting FA, cytokines (IL-6/1β and TNF-α) (Caers, et al. 2007) and 254 
adipokines (leptin and adiponectin) (Cawthorn et al. 2014; Rosen, et al. 2009). Moreover, 255 
there is often a relationship between bone loss and MAT expansion, which can coincide 256 
during ageing, osteoporosis, elevated glucocorticoids and cancer treatments. This further 257 
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suggests a close relationship between bone-specific cells and marrow adipocytes (Georgiou, 258 
et al. 2012; Moerman et al. 2004).  259 
 260 
The Diseased State  261 
The skeleton and associated bone-secreted factors provide a complex endocrine system that 262 
is finely orchestrated with other organs including the gut, brain, liver and kidney to ensure 263 
homeostatic balance and health. Indeed, bone-associated proteins act as a bridge to link 264 
complex pathways that bring together bone turnover, mineralisation, mineral and metabolic 265 
homeostasis. When these pathways become dysregulated, affected individuals may suffer 266 
from bone, muscle, and adipose pathology (Figure 2).  267 
 268 
I) Multiple myeloma and myeloma bone disease: 269 
In the instance of multiple myeloma, affected individuals with myeloma bone disease 270 
(MBD) may experience altered bone metabolism, as a consequence of myeloma cells 271 
colonising the bone marrow (Walker, et al. 2014; Xi, et al. 2016). The pathophysiology of 272 
MBD is characterised by an imbalance in osteoblast and osteoclast activity.  The resultant 273 
disruption of bone turnover is due to two distinct mechanisms. Firstly, engrafted myeloma 274 
cells are capable of secreting osteoclast-activating factors including, but not limited to, IL-6, 275 
IL-β, TNFα and parathyroid hormone-related protein. Secondly, these engrafted cells can 276 
also interact with bone marrow microenvironment-regulating cells to further encourage 277 
secretion of osteoclast-activating factors (Roodman 2010; Terpos, et al. 2014). By 278 
orchestrating this two-pronged “attack”, myeloma cells increase osteoclastic bone 279 
resorption. Further, several molecular mechanisms have been attributed to promoting 280 
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osteoblastic reduction within MBD: Wnt-antagonists Dickkopf-1 (DKK1), runt-related 281 
transcription factor 2 (Runx2), secreted frizzled related protein-2 (sFRP-2), transforming 282 
growth factor-beta (TGF-β), heparanase and hepatocyte growth factor (HGF) (Xi et al. 2016).  283 
 284 
Such mechanisms, which compromise the normal physiological bone environment, are 285 
likely linked to energetic costs and wider metabolic consequences to the individual. Indeed, 286 
energy is expended upon the synthesis and secretion of an abundance of proteins required 287 
in the bone destruction process orchestrated by osteoclasts. Furthermore, in advanced 288 
disease states lytic regions co-localise with elevated osteoclast activity and depressed 289 
osteoblastic activity. In accordance, the greater degree of bone acidification in osteoclastic 290 
resorption lacunae provides the conditions required to liberate the hormonally active form 291 
of OCN from the bone matrix via decarboxylation. An inverse correlation of serum 292 
decarboxylated OCN levels and the severity of MBD are reported in the literature (Bataille, 293 
et al. 1990). Furthermore, hypercalcemia is present at the site of bone lesions due to 294 
increased osteoclastic activity. This increased bone endocrine function represents changes to 295 
normal bone homeostasis and wider systemic and metabolic effects associated with the 296 
previously discussed roles of decarboxylated circulating OCN (i.e. increased insulin 297 
sensitivity, increased pancreatic β-cell proliferation, enhanced adipocyte secretion, and 298 
reduced insulin resistance; see Figure 3).  299 
 300 
Improved understanding of the pathogenesis of MBD has led to the identification of novel 301 
therapeutic targets. DKK1 is a key regulatory factor in the normal development of bone in 302 
adulthood, acting to inhibit osteoblastogenesis and promote differentiation of mesenchymal 303 
stem cells towards adipocytes by suppressing Wnt/beta-catenin signalling. It can be 304 
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hypothesised that the associated endocrine function of the increased MAT serves to 305 
propagate myelomagenesis and tumour growth, with elevated adipocyte numbers giving 306 
secretion of free fatty acids, signalling molecules (e.g. leptin, adiponectin) and myeloma-307 
supportive adipokines (e.g. IL-6, TNFα).  A recent study revealed that blocking of  DKK1 308 
activity (or, alternatively, the addition of DKK1 antibody) resulted in a decrease of osteolytic 309 
bone disease, with a restoration of increased osteoblast activity and decreased myeloma 310 
tumour burden (Qiang, et al. 2008). The bi-directional signalling of myeloma cells and bone 311 
cells requires further investigation to determine the impacts of these interactions on bone 312 
homeostasis and tumour growth. Despite accelerated interest in the field, to date MBD (and 313 
multiple myeloma) remain incurable: it is imperative that future work is conducted to 314 
further elucidate the molecular mechanisms underlying the disruption of the bone marrow 315 
microenvironment within the framework of this complex and multifactorial disease such 316 
that novel drugs may become a feasible reality for targeted therapy for the MBD patient. 317 
 318 
II) Diabetes:  319 
Globally, 642 million adults are predicted to have diabetes by 2040 (Atlas 2016). The diabetic 320 
complication of fragility fractures is of increasing importance, representing an undeniably 321 
large burden for health-care systems of the world. The burden of diabetic-fracture can also 322 
be considered at the individual level: fracture healing necessitates three energetically costly 323 
processes including inflammation, repair, and remodelling (Regard, et al. 2012). It is 324 
conceivable that the associated energetic cost of this exerts a direct effect on global energy 325 
metabolism of the affected individual, although to date no established link of fracture 326 
burden and energy metabolism has been acknowledged. 327 
 328 
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In type 1 diabetes mellitus (T1DM), bone mineral density (BMD) – the gold standard 329 
measure for the determination of fracture risk - is decreased, a product of decreased 330 
osteoblastogenesis and increased osteoblast death (Coe, et al. 2011; McCabe 2007). 331 
Conversely, BMD is increased in type 2 DM (T2DM), yet in both T1DM and T2DM patients 332 
have a significantly higher fracture risk as a complication of diabetic bone disease, compared 333 
to the general public (Janghorbani, et al. 2006). This indicates a wider role of under-334 
appreciated and undefined pathophysiological mechanisms responsible for diabetes-335 
associated bone fragility and highlights the shortcomings of our modern day fracture-risk 336 
assessment techniques. It is likely that many T2DM patients of high fracture risk go 337 
unidentified prior to fracture incidence, owing to the higher BMD associated with this class 338 
of diabetes. It remains possible that the physiological paradox of elevated BMD coinciding 339 
with increased fracture risk could well be explained by the higher prevalence of fall-340 
associated trauma amongst diabetic patients (Gregg, et al. 2002; Schwartz, et al. 2002).  341 
However, it is likely that the pathophysiological mechanisms that underlie bone fragility in 342 
diabetic patients are of greater complexity than initially anticipated: even when studies 343 
include falls and associated risk factors, the association between diabetes and increased 344 
fractures remains inconclusively explained (Schwartz et al. 2002).  345 
 346 
Suggested mechanisms of diabetic fractures include complications with hyperglycaemia, 347 
oxidative stress, and glycation end-product accumulation, which compromises the 348 
properties of collagen – the most abundant of the bone proteins (Napoli, et al. 2016). 349 
Furthermore, diabetes is associated with declining renal function, associated with lower 350 
BMD, and microvascular complications, which limit blood flow to the bone. Consequently, 351 
bones have decreased exposure to circulating bioactive hormones, including OCN, which 352 
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may further contribute to skeletal fragility. These factors indicate there is a poorer quality of 353 
the bone such that there is increased fracture risk for both T1DM and T2DM, despite 354 
differences in BMD between these cohorts.  355 
 356 
III) Obesity and Anorexia: 357 
Our knowledge of the pathogenicity of T2DM and bone disease is further complicated by 358 
the frequent overlap of T2DM with obesity. Indeed, a long-held concept is that obesity 359 
protects against fracture risk by increasing loading of the skeleton. Increased mechanical 360 
strain in obesity is sensed and translated by osteocytes, increased BMD. However, whilst 361 
seemingly logical, this concept has recently been debunked: obesity itself is an independent 362 
risk for fracture owing to compromised quality of bones, despite non-compromised BMD 363 
(Johansson, et al. 2014; Palermo, et al. 2016). This confounds our attempts to understand 364 
diabetes-specific endocrine mechanisms underlying diabetic-associated skeletal fragility.  365 
 366 
Obesity further manifests bone disease through mechanisms affecting metabolism. Since 367 
both marrow adipocytes and osteoblasts likely derive from a common progenitor within the 368 
BM stroma (Chen et al. 2014), and that obesity promotes the differentiation of adipocytes in 369 
WAT, it is possible that obesity may also stimulate marrow adipogenesis at the cost of 370 
osteoblast differentiation. This would result in the altered quality of the obese patient's 371 
bones, even if elevated mechanical strain may be giving rise to increased BMD.   372 
 373 
In addition, obesity is often associated with chronic inflammation. Obese individuals have 374 
an altered hormonal milieu and higher circulating levels of pro-inflammatory cytokines. 375 
Such cytokines may serve to modify the activity of the osteoclast receptor activator of NF-kB 376 
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(RANK)/RANK-Ligand (RANKL), thereby increasing osteoclastogenesis and bone 377 
resorption. In addition, the bioavailable 25 hydroxyvitamin D3 is decreased in obese 378 
individuals, likely due to storage within the excess adipose tissue, which compromises bone 379 
mineral content (Cândido and Bressan 2014). Amongst the obese population, there is also an 380 
increase in circulating bone-anabolic hormones. This includes higher levels of pancreatic 381 
hormones (insulin, amylin, and preptin), and adipose-derived factors including aromatase, 382 
leptin, and resistin (Karra and Batterham 2010).  383 
 384 
On the other end of the weight spectrum, anorexia patients also exhibit a disease-bone 385 
phenotype, with greater fracture propensity. This serious psychiatric disorder manifests in 386 
emaciation of the self-starved individual (Dede, et al. 2014). Alongside serious weight 387 
deficit, the anorexic patient further suffers from bone structural deficits, such that, the 388 
skeletal mechanical capability is impaired. These individuals experience decreased cortical 389 
radius thickness and wider endocortical diameters (Dede et al. 2014). Such micro-390 
architectural alterations increase susceptibility to bone fragility, regardless of documented 391 
BMD values. These structural defects persist even after recovery from the disease (Dede et 392 
al. 2014). In a similar fashion to the long-suffering anorexia patient, low-calorie intake 393 
during early stages of life (i.e. during skeletal development) results in decreased bone mass, 394 
increased fracture risk and osteoporosis in adulthood (Devlin et al. 2010). These defects are 395 
most harmful during adolescence when bone accrual is paramount for the development of 396 
peak bone mass. As previously discussed, anorexia (and caloric restriction) are associated 397 
with increased MAT (Fazeli, et al. 2013; Scheller and Rosen 2014). To date, over 10 distinct 398 
animal studies have found increased MAT during states of CR or starvation, such that MAT 399 
significantly increases in the proximal femur and tibia of CR mice in comparison to the 400 
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control mice (Cawthorn et al. 2014; Devlin et al. 2010). Furthermore, CR in young mice 401 
decreased serum leptin and IGF-1 levels. Despite elevated bone resorption and decreased 402 
bone formation and percentage body fat, MAT was significantly increased in CR mice 403 
(Devlin et al. 2010), suggesting that increased MAT is associated with impaired skeletal 404 
maturity; however, CR in rabbits causes bone loss without MAT expansion, suggesting that 405 
the latter is not necessary for the former (Cawthorn et al 2016). In addition to decreased 406 
circulating levels of leptin and IGF-1 during CR, decreased circulating oestradiol and 407 
increased circulating FGF21, ghrelin and cortisol/corticosterone levels have also been linked 408 
to elevated BM adiposity; thus, each of these factors has been suggested as mediators of 409 
MAT expansion during CR (Cawthorn et al. 2014; Devlin et al. 2010; Shen, et al. 2012; 410 
Suchacki, et al. 2016; Sulston and Cawthorn 2016; Syed, et al. 2008; Thompson, et al. 2004). 411 
These studies highlight the possibility that MAT may be responsible for endocrine signalling 412 
such that the propensity of fracture for the anorexic sufferer is increased. One key question 413 
is whether the highly energetic cost of fracture repair, coupled with emaciated status of the 414 
anorexic individual, promotes the differentiation of skeletal stem/stromal cells towards MAT 415 
to act as an ‘emergency storage’ of adipocytes, and thus energy, to facilitate survival during 416 
self-starvation? If so, this likely comes at the expense of osteoblasts, derived from the same 417 
skeletal progenitor, thereby further potentiating bone fragility in anorexic patients.  418 
 419 
IV) Pancreatic disease: 420 
Given the recently acknowledged bone-pancreas loop in the regulation of glucose 421 
metabolism by insulin (Faienza, et al. 2015), it is possible that pancreatic diseases such as 422 
pancreatitis or pancreatic cancer may result in altered bone homeostasis and/or endocrine 423 
function. Studies both in vitro and in vivo have revealed the osteogenic nature of insulin, 424 
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promoting cell proliferation, collagen synthesis and uptake of glucose. Insulin acts on bone 425 
by binding to the insulin receptor situated on the osteoblast. Recent studies (Ferron, et al. 426 
2010; Fulzele, et al. 2010) have revealed that osteoblast-specific insulin receptor knockout 427 
results in decreased osteoblast numbers and bone formation, coupled with reduced OCN 428 
activity. Patients with pancreatitis suffer from the loss of exocrine and endocrine functions 429 
via inflammatory processes that cause the destruction of the pancreas. Concomitantly, a loss 430 
of islet cells (αand βcells) results in a decrease in the release of glucoregulatory hormones 431 
(glucagon, insulin and pancreatic polypeptides). This compromised insulin release is likely 432 
to also compromises osteoblast-endocrine signalling to the insulin receptor. Indeed, a study 433 
by Moran et al. (1997) revealed that patients with pancreatic insufficiency, a product of 434 
chronic pancreatitis, exhibited osteopenia and osteoporosis, although they were unable to 435 
determine the pathological mechanisms underpinning this relationship. Furthermore, 436 
preptin, a peptide hormone cosecreted by pancreatic βcells with insulin and amylin has been 437 
shown to be anabolic to bone in vitro and in vivo (Cornish, et al. 2007). During osteoporosis, 438 
preptin levels are diminished, positively correlating with BMD. It is understood that preptin 439 
is involved in the pathogenesis of osteoporosis through bone formation rather than 440 
resorption. However, further studies are required to clarify whether preptin can be a new 441 
target for treating osteoporosis by promoting bone formation (Li, et al. 2013). 442 
 443 
V) Liver disease: 444 
The prevalence of patients with chronic liver disease experiencing fracture is estimated at 445 
40% (Nakchbandi 2014). Since the liver coordinates many key metabolic pathways, it is 446 
unsurprising that the experience of disease within this organ results in atypical metabolism: 447 
liver disease itself is the secondary leading cause of osteoporosis. However, there is a lack of 448 
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epidemiological data to support the true extent of osteoporosis amongst chronic liver 449 
disease sufferers (Nakchbandi 2014). The liver is central to the maintenance of health 450 
processes in the individual. For example, the liver secretes bone-health-associated factors, 451 
including IGF-I and fibronectin. In health, liver-secreted fibronectin circulates prior to 452 
infiltrating the bone matrix: upon infiltration, matrix mineralisation and subsequent 453 
microarchitectural properties of bone are favourably promoted. In addition, the liver is 454 
capable of acting as a target molecule for bone-active hormones, responding with the 455 
production of various endocrine molecules including IL-6. IL-6 can act directly to activate 456 
osteoclasts or can serve to stimulate RANKL production via osteoblasts, such that 457 
osteoclasts are indirectly activated. Further, the liver is capable of metabolising bone-active 458 
molecules, including OCN, such that the period of bioavailability is reduced. Yet, in disease 459 
states, such as non-alcoholic fatty liver disease, IL-6 is upregulated as a by-product of liver 460 
injury and attempted consequential liver regeneration: this increase, in turn, promotes bone 461 
resorption by active osteoclasts. Furthermore, in chronic liver disease states, a reported 92% 462 
of patients have vitamin D deficiency: as such, calcium is liberated from the bone via 463 
osteoclastic resorption to retain homeostasis within the blood. The net result of this is the 464 
loss of bone (Nakchbandi 2014).   465 
 466 
Perspective  467 
The last decade has witnessed growing understanding of the skeleton’s ability to act as an 468 
endocrine organ. Significant developments in cellular systems and mouse models have 469 
revealed increasingly convincing evidence in favour of the skeleton’s endocrine function 470 
(Figure 3). This adds further credence in reinforcing the importance of the skeleton for 471 
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survival beyond its mechanical roles. It makes sense, from an evolutionary perspective, that 472 
the skeleton produces hormones that regulate skeletal mineralisation, cooperating with 473 
other endocrine organs to control the metabolism of phosphate and calcium.   474 
 475 
Despite the significant advances in comprehending skeletal energy homeostasis, many 476 
questions remain unanswered. Putative investigations of other bone-secreted factors (such 477 
as NPP1 and PHOSHPO1) have revealed further candidates for links in metabolic health, 478 
including significant roles in diabetes and obesity pathology. Yet much remains to be 479 
identified about the specific mechanisms of action and novel pathways of these new 480 
candidates with regard to skeletal and metabolic homeostasis. Continued identification of 481 
bone-secreted factors and their function will aid in answering the questions of how and why 482 
bone-specific regulation of energy metabolism arose. Most recently, lipocalin (LCN2), an 483 
adipokine once thought to be exclusively secreted by adipose tissue has been shown to be an 484 
osteoblast-rich, secreted protein. LCN2 crosses the blood-brain barrier to activate the 485 
melanocortin 4 receptor, resulting in appetite suppression. Murine loss- and gain-of-function 486 
experiments demonstrated that LCN2 maintains glucose homeostasis, improve glucose 487 
tolerance and insulin sensitivity, however, more compelling human data is required to fully 488 
establish the role of LCN2 (Mosialou, et al. 2017) (Figure 3).  489 
 490 
Indeed, little is also known about the role of formation and function of MAT – does MAT 491 
contribute to the global regulation of energy metabolism by the skeleton? Does MAT 492 
provide a local reservoir of energy for bone-specific cells during bone remodelling or in 493 
pathological situations? Further understanding of the mechanisms involved in this bone-494 
metabolic axis will have many diverse implications for the management of T2DM, metabolic 495 
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syndrome, and other diseases of bone and adipose physiology. Such knowledge will reveal 496 
unidentified mechanisms that regulate energy homeostasis, thereby allowing development 497 
of novel pharmacological approaches for managing and treating skeletal and metabolic 498 
diseases, underscoring the need for continued research into the endocrine and metabolic 499 
functions of the skeleton. 500 
 501 
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Figure 1. Bone anatomy and composition 
Bone is organised into two distinct structures, cortical and trabecular.  Cortical bone accounts for 80% of the skeletal mass and 
is highly organised, consisting of concentric lamellae arranged in Haversian systems. Trabecular, or ‘spongy’ bone, possesses 
ten times the surface area of cortical bone, accounting for 20% of the bone mass and enabling bone to withstand compressive 
and tensile forces. The bone contains osteoblasts, osteocytes, and osteoclasts. Osteoblasts constitute approximately 5% of all 
bone cells and are the specialised ‘bone-building’ cells, originating from pluripotent mesenchymal stem cells (MSCs). Following 
matrix deposition and mineralisation, osteoblasts either remain on the surface of the bone as inactive lining cells; undergo 
apoptosis; or become entombed by their secreted matrix and differentiate into osteocytes. Osteocytes reside within the 
mineralised bone matrix and are organised in functional syncytia collectively referred to as the osteocytic lacunar–canalicular 
system. Osteoclasts are derived from the haematopoietic lineage and are responsible for the resorption of mineralised bone and, 
in partnership with osteoblasts, regulate remodelling of bone tissue. The bone marrow further provides the haematopoietic 
niche, which supports the survival, self-renewal, and differentiation of the haematopeiotic stem cell (HSC). HSCs are capable of 
differentiation into two cell types: firstly, the common myeloid progenitor, which further differentiates to give rise to a number 
of blood cells including platelets, eosinophils, basophils, neutrophils, monocytes, and erythrocytes; and secondly, the common 
lymphoid progenitor, which further differentiates to form B- and T-cells of the immune system. Within the bone marrow 
cavity, maintenance of the haematopoietic niche is orchestrated through vascular niches, which balance quiescence of HSC, 
proliferation and also regeneration following injury to the bone marrow. This regulation of HSC homeostasis involves intrinsic 
and extrinsic signals from the niche, including bound or secreted molecules, contractile force, or even temperature. 
Haematological malignancies, or chemotherapy/radiation as a treatment for the disease, causes a limit to the regenerative and 
differentiation potentials of HCSs, causing a functional deficit (further discussed within text – see ‘Disease and Bone’ section).  
 
Figure 2 Regulators of bone volume, muscle mass, subcutaneous and marrow adipose 
tissue. 
(Arrow key: Red solid – increased; green solid – decreased) 
Schematic representation of the key regulators of bone volume, muscle mass, subcutaneous and marrow adipose tissue. It is 
interesting to highlight that both calorie restriction and glucocorticoids result in the loss of adipose tissue, muscle and bone 
(discussed further in the text). 
 
Figure 3 Integrative model of the regulation of the new endocrine functions bone, muscle, 
and marrow adipose tissue. 
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(Arrow key: Black solid – accepted; black dashed – speculative; red – inhibitory) 
Insulin secretion from the pancreas acts upon the insulin receptor on the osteoblast, which subsequently inhibits Forkhead box 
protein O 1 (FoxO1)  expression and suppresses twist basic helix-loop-helix transcription factor 2 (Twist2), favouring bone 
resorption via osteoclast activation.  The adipocyte derived hormone leptin has been shown to have two opposing roles, acting 
centrally to inhibit bone mass accrual and peripherally, increasing osteoblast number and activity. The acidic pH generated in 
the resorption lacunae decarboxylates OCN on its three glutamic acid residues (GLU13, GLU17 and GLU20) which enable it to 
be released from the bone matrix into the general circulation. Once circulating, OCN can regulate global energy metabolism via 
the stimulation of insulin secretion and β-cell proliferation in the pancreas; energy expenditure by muscle; and insulin 
sensitivity in adipose tissue, muscle, and liver. Furthermore, OCN favours hippocampal development in offspring; brain 
function in adults; and male fertility by stimulating testosterone synthesis in leydig cells of the testis. A bone-muscle feed 
forward axis exists where systemic under-carboxylated OCN signals to myofibers favouring uptake and subsequent catabolism 
of glucose and fatty acids, facilitating physical adaptation to exercise and release of exercise-induced IL-6. The latter drives the 
production of bioactive OCN. Adiponectin release from bone marrow adipose tissue may act to indirectly increase bioactive 
OCN via suppressing osteoblast proliferation, potentially favouring osteoclast activity. Another possibility is that excess local 
OCN production is responsible, at least in part, for elevated adiponectin production from MAT, however, this remains unclear.  
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